Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis a step toward personalized treatment

JAMA Dermatology

Volumn 151, Issue 6, 2015, Pages 616-622

  Menting, Stef P ^a   Coussens, Emma ^b   Pouw, Mieke F ^a,c   Van Den Reek, Juul M P A ^d   Temmerman, Linda ^e   Boonen, Hugo ^f   De Jong, Elke M G J ^d   Spuls, Phyllis I ^a   Lambert, Jo ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Jan Van Breemen Research Institute/Reade   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Maria Middelares Hospital   (Belgium)

^f Heilig Hart Ziekenhuis   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED;

ADULT; AREA UNDER THE CURVE; ARTICLE; BELGIUM; BODY MASS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NETHERLANDS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RECEIVER OPERATING CHARACTERISTIC; SECONDARY CARE CENTER; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; UNIVERSITY HOSPITAL; ALGORITHMS; BLOOD; CLINICAL TRIAL; COHORT STUDIES; HUMANS; INDIVIDUALIZED MEDICINE; METHODS; PATHOLOGY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BELGIUM; COHORT STUDIES; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; PSORIASIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84931062985     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.5479     Document Type: Article

References (20)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
2. Saurat JH, Stingl G, Dubertret L, et al; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-566.
3. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J AmAcad Dermatol. 2012;66(2):241-251.
4. Gniadecki R, Kragballe K, DamTN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091-1096.
5. Menting SP, SitaramAS, Bonnerjee-van der Stok HM, de Rie MA, Hooft L, Spuls PI. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol. 2014;171(4):875-883.
6. van Lumig PP, van de Kerkhof PC, Boezeman JB, Driessen RJ, de Jong EM. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs non-naive patients. J Eur Acad Dermatol Venereol. 2013;27(5):593-600.
7. Vena GA, Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics. 2007;1(2):93-103.
8. Menting SP, van Lumig PP, de Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol. 2014;150(2):130-136.
9. Pouw MF, Krieckaert CL, Nurmohamed MT, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74(3):513-518.
10. Krieckaert CL, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2015;74(2):361-368.
11. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460-1468.
12. Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011;372(1-2):196-203.
13. van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104-109.
14. Rispens T, van der Kleij D. Reply to Ruiz-Arguello et al: comparison study of two commercially availablemethods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med. 2013;51(12):e291-e292.
15. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(suppl 2):10-16.
16. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10.
17. Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40(1):39-42.
18. Edson-Heredia E, Sterling KL, Alatorre CI, et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol. 2014;134(1):18-23.
19. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J AmAcad Dermatol. 2010;63(3):448-456.
20. Karczewski J, Poniedziaęk B, Rzymski P, Adamski Z. Factors affecting response to biologic treatment in psoriasis. Dermatol Ther. 2014;27(6):323-330.